A recent study examined whether the Lung Immune Prognostic Index was associated with resistance to immunotherapy in patients with advanced non-small cell lung cancer.
A comparative effectiveness study examined the costs associated with short-course radiation therapy versus long-course chemoradiation for locally advanced rectal adenocarcinoma.
The ACCC annual survey to identify emerging trends across US cancer programs found costs of drugs and new treatment modalities as the largest threat to future cancer program growth.
A plasma-based next-generation sequencing option allows for sensitive detection and monitoring of mutations in advanced non-small cell lung cancer.
The FDA has approved an injection in combination with an established oral therapy for the treatment of acute promyelocytic leukemia.
Despite a trend toward increased metric use, approximately 50% of patients with RA are not routinely assessed with a disease activity metric, according to the results of a recent survey.
The growing use of effective treatment strategies for metastatic cancer in the brain has not been documented in certain patient populations.
A recent systematic review analyzed the predictors of emotional distress a year or more after a cancer diagnosis.
Certain subgroups of patients with NSCLC are underrepresented in clinical trials for newly approved PD-1 inhibitors and are needed to inform real-world treatment decisions.
The FDA expanded the approved use of a therapy for metastasized breast cancer with a certain germline genetic mutation.